[(benzoyloxymethoxy)carbonyloxy]succinimide | 886053-12-9

• 分子结构分类: 有机化合物 - 苯类化合物 - 苯和取代衍生物
• 英文名称: [(benzoyloxymethoxy)carbonyloxy]succinimide
• 英文别名: N-[(benzoyloxymethoxy)carbonyloxy]succinimide；({[(2,5-Dioxopyrrolidin-1-yl)oxy]carbonyl}oxy)methyl benzoate；(2,5-dioxopyrrolidin-1-yl)oxycarbonyloxymethyl benzoate
• CAS: 886053-12-9
• 化学式: C₁₃H₁₁NO₇
• 分子量: 293.233
• InChiKey: AVJVDICYLYUKJN-UHFFFAOYSA-N

计算性质

• 辛醇/水分配系数(LogP)：
  1.3
• 重原子数：
  21
• 可旋转键数：
  7
• 环数：
  2.0
• sp3杂化的碳原子比例：
  0.23
• 拓扑面积：
  99.2
• 氢给体数：
  0
• 氢受体数：
  7

反应信息

• 作为反应物：
  描述：

  tranexamic acid 、 [(benzoyloxymethoxy)carbonyloxy]succinimide 以 MTBE acetone water 为溶剂， 以to yield the title compound 7 (445 mg, 66% yield) a white powder的产率得到trans-4-{[(benzoyIoxy)methoxycarbonyl]aminomethyl}-cyclohexanecarboxylic acid
  参考文献：
  名称：

  ACYLOXYALKYL CARBAMATE PRODRUGS OF TRANEXAMIC ACID, METHODS OF SYNTHESIS AND USE

  摘要：

  本文公开了trans-4-（氨甲基）-环己烷羧酸的酰氧基烷基氨基甲酸酯前药、其制药组合物、制备trans-4-（氨甲基）-环己烷羧酸酯前药的方法，以及使用trans-4-（氨甲基）-环己烷羧酸酯前药和制药组合物治疗或预防各种疾病或障碍的方法。本文还公开了适用于口服、局部使用和使用缓释剂型的酰氧基烷基氨基甲酸酯前药和制药组合物。

  公开号：

  US20080153898A1

文献信息

• TRIENTINE PRODRUGS, PHARMACEUTICAL COMPOSITIONS THEREOF, AND METHODS OF USE
  申请人：Nguyen Mark Quang

  公开号：US20170129868A1

  公开（公告）日：2017-05-11

  Trientine prodrugs, pharmaceutical compositions comprising the trientine prodrugs, and methods of using trientine prodrugs and pharmaceutical compositions thereof for treating Wilson's disease.

  Trientine前药，包含Trientine前药的药物组合物，以及使用Trientine前药和药物组合物治疗威尔逊病的方法。
• TIOPRONIN PRODRUGS, PHARMACEUTICAL COMPOSITIONS THEREOF, AND METHODS OF USE
  申请人：Nguyen Mark Quang

  公开号：US20170129867A1

  公开（公告）日：2017-05-11

  Tiopronin prodrugs, pharmaceutical compositions comprising the tiopronin prodrugs, and methods of using tiopronin prodrugs and pharmaceutical compositions thereof for treating liver, kidney, lung, neurological, inflammatory, and autoimmune disorders including non-alcoholic steatohepatitis, Wilson's disease, cystinuria, irritable bowel disorder, ulcerative colitis, rheumatoid arthritis, chronic obstructive pulmonary disease, interstitial lung disease, asthma, cystic fibrosis, Parkinson's disease, and Huntington's disease.

  Tiopronin前药、包含Tiopronin前药的药物组合物，以及使用Tiopronin前药和药物组合物治疗肝脏、肾脏、肺部、神经学、炎症和自身免疫障碍的方法，包括非酒精性脂肪肝炎、威尔逊病、胱氨酸尿症、肠易激综合症、溃疡性结肠炎、类风湿性关节炎、慢性阻塞性肺病、间质性肺病、哮喘、囊性纤维化、帕金森病和亨廷顿病。
• [EN] CYSTEINE, N-ACETYLCYSTEINE AND PENICILLAMINE PRODRUGS, PHARMACEUTICAL COMPOSITIONS THEREOF, AND METHODS OF USE<br/>[FR] PROMÉDICAMENTS CYSTÉINE, N-ACÉTYLCYSTÉINE ET PÉNICILLAMINE, LEURS COMPOSITIONS PHARMACEUTIQUES, ET LEURS PROCÉDÉS D'UTILISATION
  申请人：NGUYEN MARK QUANG

  公开号：WO2018174839A1

  公开（公告）日：2018-09-27

  Cysteine, N-acetylcysteine, and penicillamine prodrugs, pharmaceutical compositions comprising the cysteine, N-acetylcysteine, and penicillamine prodrugs, and methods of using cysteine, N-acetylcysteine, and penicillamine prodrugs and pharmaceutical compositions thereof for treating liver, kidney, lung, neurological, inflammatory, and autoimmune disorders including paracetamol overdose, non-alcoholic steatohepatitis, Wilson's disease, cystinuria, irritable bowel disorder, ulcerative colitis, rheumatoid arthritis, chronic obstructive pulmonary disease, interstitial lung disease, asthma, cystic fibrosis, Parkinson's disease, and Huntington's disease.

  半胱氨酸、N-乙酰半胱氨酸和青霉胺前药，包括半胱氨酸、N-乙酰半胱氨酸和青霉胺前药的药物组合物，以及使用半胱氨酸、N-乙酰半胱氨酸和青霉胺前药及其药物组合物治疗肝脏、肾脏、肺部、神经系统、炎症性和自身免疫性疾病，包括对乙酚过量、非酒精性脂肪肝炎、威尔逊氏病、半胱氨酸尿症、肠易激综合征、溃疡性结肠炎、类风湿关节炎、慢性阻塞性肺病、间质性肺病、哮喘、囊性纤维化、帕金森病和亨廷顿病的方法。
• Acyloxyalkyl carbamate prodrugs, methods of synthesis, and use
  申请人：Gallop A. Mark

  公开号：US20060111325A1

  公开（公告）日：2006-05-25

  Acyloxyalkyl carbamate prodrugs of 3-aminopropylphosphonous acid, 3-aminopropylphosphinic acid, and analogs thereof, pharmaceutical compositions comprising acyloxyalkyl carbamate prodrugs of 3-aminopropylphosphonous acid, 3-aminopropylphosphinic acid, and analogs thereof, methods of making prodrugs of 3-aminopropylphosphonous acid, 3-aminopropylphosphinic acid, and analogs thereof, methods of using prodrugs of 3-aminopropylphosphonous acid, 3-aminopropylphosphinic acid, and analogs thereof and pharmaceutical compositions thereof for treating or preventing diseases or disorders such as spasticity or gastroesophageal reflux disease are disclosed. Acyloxyalkyl carbamate prodrugs of 3-aminopropylphosphonous acid, 3-aminopropylphosphinic acid, and analogs thereof and sustained release oral dosage forms thereof, which are suitable for oral administration, are also disclosed.

  3-氨基丙基膦酸、3-氨基丙基膦酸和其类似物的酰氧烷基氨基甲酸酯前药，包括3-氨基丙基膦酸、3-氨基丙基膦酸和其类似物的酰氧烷基氨基甲酸酯前药的药物组合物，制备3-氨基丙基膦酸、3-氨基丙基膦酸和其类似物的前药的方法，使用3-氨基丙基膦酸、3-氨基丙基膦酸和其类似物的前药的方法，以及用于治疗或预防痉挛或胃食管反流病等疾病或紊乱的药物组合物。还公开了适用于口服的酰氧烷基氨基甲酸酯前药、3-氨基丙基膦酸、3-氨基丙基膦酸和其类似物的持续释放口服剂型。
• CYSTEINE, N-ACETYLCYSTEINE, AND PENICILLAMINE RELATED COMPOUNDS, PHARMACEUTICAL COMPOSITIONS THEREOF, AND METHODS OF USE
  申请人：Nguyen Mark Quang

  公开号：US20170081280A1

  公开（公告）日：2017-03-23

  Cysteine, N-acetylcysteine, and penicillamine related compounds, pharmaceutical compositions comprising the cysteine, N-acetylcysteine, and penicillamine related compounds, and methods of using cysteine, N-acetylcysteine, and penicillamine related compounds and pharmaceutical compositions thereof for treating liver, kidney, lung, neurological, inflammatory, and autoimmune disorders including paracetamol overdose, non-alcoholic steatohepatitis, Wilson's disease, cystinuria, irritable bowel disorder, ulcerative colitis, rheumatoid arthritis, chronic obstructive pulmonary disease, interstitial lung disease, asthma, cystic fibrosis, Parkinson's disease, and Huntington's disease.

  半胱氨酸、N-乙酰半胱氨酸和青霉胺相关化合物，包括半胱氨酸、N-乙酰半胱氨酸和青霉胺相关化合物的制药组合物，以及使用半胱氨酸、N-乙酰半胱氨酸和青霉胺相关化合物及其制药组合物治疗肝脏、肾脏、肺部、神经、炎症和自身免疫性疾病，包括对乙酰氨基酚过量、非酒精性脂肪性肝炎、威尔逊病、囊石症、肠易激综合征、溃疡性结肠炎、类风湿性关节炎、慢性阻塞性肺疾病、间质性肺疾病、哮喘、囊性纤维化、帕金森病和亨廷顿病等疾病的方法。